Ægle will invest in new and emerging technologies that have been proven to work in academic settings and bringing them to commercial industry
Commercialisation of innovations
Ægle is in the process of acquiring the patents for two nanoparticle based medical innovations, and is actively seeking to commercialise these technologies while seeking out additional complimentary innovations:
Conjugation of proteins onto nanoparticle surfaces (bi-specific nanoparticles comprising a targeting antibody population and an immune-activating antibody population )
Nanoparticle composition for treating diseases of posterior segment of the eye (Ophthalmic topical compositions
Along with many other sectors and applications, Nanoparticles will play a signifcant role in the future of pathogen testing.
Together with our experienced partners in the medical device (in vitro diagnostic) field, we plan to develop a reliable, rapid, and affordable test kit for use in a countless range of applications.
The addresable market is vast, from the common cold, corona viruses, and other viral infections in humans to all order of diseases including applications in veterinary science, environmental testing and drug and food safety.